Navigation Links
Gene variant identified as a heart disease risk factor for women
Date:7/22/2014

When it comes to heart disease, Dr. Ross Feldman says women are often in the dark. Historically, it was thought that heart disease was a men's-only disease, however, data has shown that post-menopausal women are just as likely as men to get heart disease and are less likely to be adequately diagnosed and treated. New research from Western University published online this week in the British Journal of Clinical Pharmacology brings to light a genetic basis for heart disease in women and helps to identify which women are more prone to heart disease.

The study, led by Dr. Feldman, a clinical pharmacologist at London Health Sciences Centre and a researcher at the Schulich School of Medicine & Dentistry's Robarts Research Institute, identifies a common gene variant in women for the G-protein coupled estrogen receptor 30 (GPER) that makes them significantly more likely to have high blood pressure, the single biggest risk factor for heart attack and stroke.

GPER, when functioning normally, is activated in part by the hormone estrogen and has been previously shown to relax the blood vessels, and in turn, lower blood pressure. This new study demonstrates that many women have a less functional form of GPER, increasing their risk of developing high blood pressure.

The research looked at the effect of expression of the GPER gene variant versus the normal GPER gene in the vascular smooth muscle cells as well as its association with blood pressure in humans. It also looked at the frequency of the gene variant in a group of women referred a tertiary care clinic at London Health Sciences Centre. The study found that women, but not men, carrying the GPER gene variant had higher blood pressure, and almost half of women who attended a hard-to-treat blood pressure clinic, where Dr. Feldman is a physician, expressed the variant. Twice as many women than men with hard to treat hypertension carried the gene.

"This is one step in understanding
'/>"/>

Contact: Crystal Mackay
crystal.mackay@schulich.uwo.ca
519-661-2111 x80387
University of Western Ontario
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Common gene variants account for most of the genetic risk for autism
2. Splice variants reveal connections among autism genes
3. Certain genetic variants may identify patients at higher risk of bladder cancer recurrence
4. Gene variants protect against relapse after treatment for hepatitis C
5. Researchers identify genomic variant associated with sun sensitivity, freckles
6. Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
7. Noodles Box launches variants in serving size
8. Gene variant ID could lead to better fatty liver disease diagnosis
9. Common gene variants explain 42 percent of antidepressant response
10. An international study identifies new DNA variants that increase the risk for cancer
11. eVariant Welcomes Advocate Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... ... ... “would be” entrepreneurs, starting a new business can prove to be daunting from the viewpoint ... needs be a major obstacle. , The U.S. has always been the land of ... The risks of starting a business can be high but the rewards can be well ...
(Date:8/1/2015)... ... , ... Back packs can be dangerous? Whaaat?! , Not the danger that ... on a kid's spine. With school starting again, most kids will be asking for ... are aware of how to help them prevent injuries by understanding backpack safety. , ...
(Date:8/1/2015)... NY (PRWEB) , ... August 01, 2015 , ... Calvary ... scroll currently housed at their Bronx campus. The goal is to bring this Torah ... again be used in Jewish rituals and religious services. , Scroll No. 515, ...
(Date:8/1/2015)... York, NY (PRWEB) , ... August 01, 2015 , ... ... Vine cyberespionage group , who are thought to have been behind the attack on ... the topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... ... 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked ... and was greeted by friends and family. He visited CCAR and left an inspirational ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... DIEGO, Dec. 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ... on commercializing proprietary product candidates for the treatment,of ... M. Culley,ADVENTRX,s chief business officer, is scheduled to ... as part of a panel on Better Drugs ...
... Human Resources Professional Brings Diverse Expertise, MIAMI, ... biotherapeutic products to healthcare providers, is pleased,to announce ... Vice President of,Human Resources. Ms. Lopez was most ... & Johnson Company. Her 17-year career began,in Human ...
... States may be less likely to report a family history ... prevention strategies according to a new study. Dr. Heather Orom ... colleagues argue that as a result of being less likely ... as strong a predictor of cancer risk in immigrant populations. ...
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... improvement across all ... survival -, ATLANTA, Dec. 9 Millennium Pharmaceuticals,Inc. ... results from the,682 patient, randomized, Phase III VISTA(1) trial. ... for stem cell,transplantation (SCT). The trial compared VELCADE, melphalan ...
Cached Medicine News:Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Immigrant patients less likely to report family history of cancer 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 2Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 3Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 4Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 5Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 7
(Date:7/31/2015)... 2015 According to a new ... (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, ... Analysis & Forecast to 2019", published by MarketsandMarkets, the ... Million 2014 and is estimated to grow to $1,425.7 ... from 2014 to 2019. Browse 41 ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
... March 14, 2012 Brainlab wins coveted ,red dot ... world submitted 4,515 designs altogether to the international product ... received the globally sought after red dot in product ... technology. This advanced surgical navigation system for the brain ...
Cached Medicine Technology:Vaccines - Asia 2Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012 2Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. No cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Medicine Products: